NICE urges annual NHS checks for 4 million women with PMOS

The UK National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending that women with polyendocrine metabolic ovarian syndrome (PMOS)—formerly known as polycystic ovarian syndrome—be investigated and offered annual health reviews through the NHS. The condition, affecting up to four million women in the United Kingdom, is described as “common but often overlooked” and linked to insulin resistance, type‑2 diabetes, cardiovascular disease, mental‑health issues and pregnancy complications.

Annual reviews are to include blood‑pressure monitoring, glucose‑tolerance testing, and evaluation of menstrual regularity, with the aim of early detection of long‑term risks. The guideline advises against NHS‑funded laser or light‑based hair‑removal treatments for hirsutism, citing a lack of clinical evidence and an estimated cost of up to £100 million per year. It also calls for awareness of higher prevalence among Black, Asian and mixed‑ethnicity women.

Consultation on the draft runs from 1 July to 11 August 2026, with final guidance expected in December 2026. NICE officials emphasize that a simple yearly review is a key step toward consistent care, earlier diagnosis and better management of both physical and mental health impacts.